+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Compliance to recommended liver function monitoring in patients on statin therapy

Compliance to recommended liver function monitoring in patients on statin therapy

Cardiovascular Therapeutics 27(2): 96-100

Product information and national guidelines consistently recommend the estimation of serum alanine aminotranferase (ALT) before and after approximately 3 months as part of risk management following initiation of statin therapy. The aim of this study was to determine compliance to the recommendations for monitoring ALT in patients initiated on statin therapy. The prevalence of abnormal serum ALT levels was also evaluated and compared with current data. We performed a retrospective observational audit of the Medicine's Monitoring Unit (MEMO) prescribing record-linkage database, which includes evidence of prescribing and biochemistry results of all patients in Tayside, Scotland. We examined patients with first-time statin prescriptions and evaluated all laboratory liver function tests recorded before and after prescriptions from 1st January 2002 to 31st December 2002. Of the 5717 patients identified, 54% were male and the subjects had a mean age of 62 +/- 14 standard deviation (SD) years. The prescriptions yielded five types of statin and included the start date, dose, and number of tablets. In total, 1455 (25%) patients had no biochemistry data at all from the year 2002, and despite the 75% of patients who had an ALT measurement, over 90% of patients did not follow the current recommendations. The prevalence of elevated transaminases was consistent with published data in that significant elevation occurred in 1.9% of subjects. Adherence to the recommended laboratory monitoring for patients first prescribed with statin therapy is low in Tayside. Adverse drug reactions need to be more closely monitored by all healthcare professionals involved in prescribing. Monitoring can highlight abnormalities and therefore reduce potentially damaging effects.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 052264233

Download citation: RISBibTeXText

PMID: 19426246

DOI: 10.1111/j.1755-5922.2009.00082.x

Related references

Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes. Diabetes and Vascular Disease Research 8(2): 160-172, 2011

Monitoring preventive therapy patients for liver disease as well as compliance. Chest 68(2): 178-180, 1975

Compliance with recommended self-monitoring of blood glucose in patients with Type 1 diabetes mellitus. Diabetologia 46(Supplement 2): A90, 2003

Is it possible to improve long-term compliance of patients to statin therapy?. Vnitrni Lekarstvi 63(10): 663-666, 2018

A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. Journal of Cardiology 60(1): 12-17, 2013

A peri-operative statin update for non-cardiac surgery. Part I: The effects of statin therapy on atherosclerotic disease and lessons learnt from statin therapy in medical (non-surgical) patients. Anaesthesia 63(1): 52-64, 2007

Is there value in liver function test and creatine phosphokinase monitoring with statin use?. American Journal of Cardiology 94(9a): 30f-34f, 2004

Benefits of statin therapy and compliance in high risk cardiovascular patients. Vascular Health and Risk Management 6: 843-853, 2010

Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients. Diabetes and Vascular Disease Research 7(4): 296-299, 2011

Reducing liver function tests for statin monitoring: an observational comparison of two clinical commissioning groups. British Journal of General Practice 67(656): E194-E200, 2017

Correlation of compliance to statin therapy with lipid profile and serum HMGCoA reductase levels in dyslipidemic patients. Indian Heart Journal 69(1): 6-10, 2017

Aggressive statin therapy recommended for diabetics. Lancet (North American Edition) 352(9144): 1911, Dec 12, 1998

Statin Therapy Does Not Reduce Liver Fat Scores in Patients Receiving Antiretroviral Therapy for HIV Infection. Clinical Gastroenterology and Hepatology 2018, 2018

Statin adverse effects: patients' experiences and laboratory monitoring of muscle and liver injuries. International Journal of Clinical Pharmacy 37(2): 355-364, 2016

A retrospective study of compliance with recommended hematologic monitoring of carbamazepine. Dicp 24(12): 1166-1168, 1990